H.C. Wainwright Sticks to Its Buy Rating for Sol-Gel Technologies (SLGL)

By Austin Angelo

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Sol-Gel Technologies (SLGLResearch Report) today and set a price target of $23.00. The company’s shares closed last Monday at $8.29.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -2.6% and a 43.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries, Turning Point Therapeutics, and Biospecifics Technologies.

Sol-Gel Technologies has an analyst consensus of Moderate Buy, with a price target consensus of $23.00.

See today’s analyst top recommended stocks >>

Based on Sol-Gel Technologies’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $7.35 million. In comparison, last year the company had a GAAP net loss of $7.71 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sol-Gel Technologies Ltd. is a clinical-stage dermatology company, which focuses on identifying, developing and commercializing topical dermatological drug products for the treatment of skin diseases. Its products include VERED, TWIN and SIRS-T. The company was founded by David Avnir and Alon Seri-Levy on October 28, 1997 and is headquartered in Ness Ziona, Israel.